- Home
- BCH vs UTHR Comparison
BCH vs UTHR Comparison
Compare BCH & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCH
- UTHR
- Stock Information
- Founded
- BCH 1893
- UTHR 1996
- Country
- BCH Chile
- UTHR United States
- Employees
- BCH N/A
- UTHR N/A
- Industry
- BCH Commercial Banks
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- BCH Finance
- UTHR Health Care
- Exchange
- BCH Nasdaq
- UTHR Nasdaq
- Market Cap
- BCH 12.5B
- UTHR 14.4B
- IPO Year
- BCH 2002
- UTHR 1999
- Fundamental
- Price
- BCH $26.47
- UTHR $304.59
- Analyst Decision
- BCH Hold
- UTHR Buy
- Analyst Count
- BCH 1
- UTHR 12
- Target Price
- BCH $23.00
- UTHR $388.25
- AVG Volume (30 Days)
- BCH 327.7K
- UTHR 499.6K
- Earning Date
- BCH 04-29-2025
- UTHR 04-30-2025
- Dividend Yield
- BCH 7.91%
- UTHR N/A
- EPS Growth
- BCH N/A
- UTHR 24.38
- EPS
- BCH 0.01
- UTHR 24.64
- Revenue
- BCH $2,675,332,916.00
- UTHR $2,877,400,000.00
- Revenue This Year
- BCH $18.71
- UTHR $11.70
- Revenue Next Year
- BCH $5.56
- UTHR $6.50
- P/E Ratio
- BCH $11.01
- UTHR $12.46
- Revenue Growth
- BCH 0.95
- UTHR 23.63
- 52 Week Low
- BCH $21.19
- UTHR $221.53
- 52 Week High
- BCH $28.64
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- BCH 46.64
- UTHR 39.02
- Support Level
- BCH $25.81
- UTHR $308.43
- Resistance Level
- BCH $27.39
- UTHR $318.40
- Average True Range (ATR)
- BCH 0.42
- UTHR 9.26
- MACD
- BCH -0.20
- UTHR 1.20
- Stochastic Oscillator
- BCH 25.09
- UTHR 29.88
About BCH Banco De Chile ADS
Operating under three separate brand names (Banco de Chile, Banco Edwards-Citi, and Banco CrediChile) Banco de Chile is the second largest in the country by loans and third largest by deposits. Banco de Chile generates most of its net interest income (roughly 60% of total revenue) from its mortgage, unsecured consumer credit lines, and commercial loans, with 25% of its outstanding loans being made to firms with more than 10,000 million CLP in revenue. Outside of its banking business, Banco de Chile is the largest asset manager in the country and one of the largest security brokerages, supporting its substantial fee-based revenue.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.